Connect with us

Market

Are You Investing Into The Biotech Dip? CASI Pharmaceuticals Inc (NASDAQ:CASI), Global Equity International Inc (OTCBB:GEQU), SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF)

Published

on

On Wednesday Richmond Federal Reserve President Jeffrey Lacker stated a brief occurrence of upsetting economic information that has done little to alter his outlook for the U.S economy. Lacker, who voted for an interest rate increase in September against the majority of Fed policymakers who choose to keep rates steady, stated he has not decided on how he will vote at the Oct. 27th-28th meeting. Although he was not persuade much by a slowdown in job growth and weaker-than-expected retail sales in September. “It doesn’t change my outlook much,” he told Fox Business in an interview hopefully his stance doesn’t impact the value of biotech stock such as:

CASI Pharmaceuticals Inc (NASDAQ:CASI) is a public, biopharma company dedicated to certain therapeutics that focus on cancer and other unmet medical needs. In a recent announcement CASI Pharmaceuticals Inc (NASDAQ:CASI) revealed that its oncology drug candidate, ENMD-2076 received Orphan Drug designation from the European Medicines Agency for the treatment of hepatocellular carcinoma (HCC), including fibrolamellar carcinoma, a rare type of HCC. In the past 30 days beginning on September 15 to October 14th CASI has seen a large increase in price of 78.43%. This new designation gives CASI 10 years of market exclusivity in EU after ENMD-2076 receives marketing authorization there. The product was previously granted Orphan Drug designation for the treatment of HCC by US Food and Drug Administration last year and provides CASI with a 7-year market exclusivity in the country after its New Drug Application approval.

Why Are Investors Scrambling For Shares Of THIS Biotechnology Stock?

Global Equity International Inc (OTCBB:GEQU) through its wholly-owned subsidiary Global Equity Partners Plc., advises worldwide business leaders with their most crucial decisions and opportunities dealing with growth, capital needs, structure and the development of a global presence. With locations in Dubai and London, Global Equity has built a strong relationships in the US, UK, Central Europe, the Middle East and South East Asia to help clients in realizing their full value and potential by bringing them to external capital and resources that place an emphasis on collaborative thinking. Global Equity International Inc (OTCBB:GEQU) Is very pleased to release the news about a strategic partnership agreement with the “Middle East Prospect Exhibition” (“MEPEX” -www.mepexonline.com), to work as their exclusive selected Financial Partner for capital raising, Advisory and Public Listings for all of the MEPEX participants. GEQU has seen a major price increase in the past 3 months of 1022.73% making them a penny stock to watch for shareholders invested in the biotech sector.

WHAT BIOTECH STOCK ARE STREET ANALYSTS CALLING “THE NEXT WINNING STOCK”?

SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) Who’s headquarters are located in Rehovot Israel, is in the business of developing, manufacturing and promoting biological products for human healthcare. The Company’s flagship product, Sci‐B‐Vac™, is a recombinant 3rd generation hepatitis B vaccine. SCIVAC THERAPEUTICS INC (OTCMKTS:SVACF) announced that its wholly-owned subsidiary SciVac Ltd. has obtained the go-ahead from the Israeli Ministry of Health to progress further on all standard manufacturing,involving labeling and release of Sci-B-Vac(TM) to the market, following corrective actions to the automated labeling system and a overview of the Company’s facilities earlier in the month of September. SVACF is up from last Friday’s close increasing 13% following highs of $0.0195 on Tuesday. In past announcements, it was noted that Opko Health, Inc. (OPKO) had a 45% stake in SciVac. Sci-B-Vac has displaying a performance in 20+ company-sponsored or investigator- initiated trials, dealing with more than 5000 who have enrolled while also being administered to over 500,000 patients to date, with favorable safety and efficacy profiles according to company data.

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading

Market

Rockwell Medical Inc (NASDAQ: RMTI): Premium Members Made A Quick 20% Profit In 24 Hours

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy Rockwell Medical Inc (NASDAQ: RMTI) yesterday (march 18th) at $5.42. Now look at the price of the stock – its up 20% at $6.55 from our buy price. This is how easy money they made. If you had invested $5,000 in RMTI, it could had been moved up to $6,000. It’s not yet late, join us at info@tradersinsights.com

Continue Reading

Market

Sorrento Therapeutics Inc (NASDAQ: SRNE): Members Made A Hefty 15% Profit In 24 Hours

Published

on

By

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/

 JOIN US NOW: For Details Contact us at info@tradersinsights.com

 Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy Sorrento Therapeutics Inc (NASDAQ: SRNE) yesterday (march 18th) at $2.67. Now look at the price of the stock – its up 15% at $3.23 from our buy price. This is how easy money they made. If you had invested $5,000 in SRNE, it could had been moved up to $5,750.  It’s not yet late, join us at info@tradersinsights.com

Continue Reading
Advertisement

Trending